Anti-infective Agents : Cephalosporins : First Generation Cephalosporins
ILICE1 “Licef-A injection ” 1 gm/vial
IS601 “S-60 Injection.” 1 gm/vial
ORECE2 “Recef capsule ” 250 mg/cap
適應症：葡萄球菌、鏈球菌、肺炎雙球菌、腦膜炎球菌、及其他具有感受性細菌引起之感染症。
Usual dose:
Susceptible infections: IV
Adult: 500 mg q4-6h.
Pediatric: 50-100 mg/kg/day in 4 divided doses; max. 4 g/day.
Respiratory tract infection: PO
Adult: 250 qid or 500 mg q12h; lobar pneumonia, 500 mg q6h or 1 g q12h.
Skin/skin structure infection: PO
Adult: 250 mg qid or 500 mg q12h.
Urinary tract infection: PO
Adult: uncomplicated, 500 mg q12h; serious, 500 mg q6h; severe or chronic, up to 1 g q6h.
Otitis media: PO
Pediatric: 25-50 mg/kg/day divided q6-12h; otitis due to H. influenzae, 75-100 mg/kg/day divided q6-12h; max. 4 g/day.
Dose adjustment:
Renal failure: CrCl 10-50 ml/min, 50% usual dose, normal interval; CrCl < 10 ml/min, 25% usual dose, normal interval.
Contraindication:
Hypersensitivity to cephradine products/cephalosporins, penicillins; history of colitis/gastrointestinal disorders.
Adverse effect:
Common: diarrhea, nausea, vomiting, rash.
Serious: neutropenia.